Navigation Links
INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:3/18/2009

rMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. Arpida Interim Results for six Months to 30 June 2007
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
5. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
6. IsoTis Reports Interim Results of Vote for Integra Merger
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
10. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
11. VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Four-dimensional (4-D) printing develops materials that ... stimuli such as changes in temperature. This advanced ... in multiple industries.  In the near future, 4-D ... objects ranging from human organs to parts used ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, the ... molecules, became available for purchase in Australia and New Zealand, ... RENU 28 works is, if you think about the definition ... of cellular renewal within your body. If you think about ... of cellular renewal. What RENU 28 does is it works ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, Inc. ... a conference call to provide an update on ... Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) ... web cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference ... completion through September 2, 2014 at (888) 203-1112 ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... 15 /PRNewswire-Asia-FirstCall/ -- China,Biologic Products, Inc. (OTC Bulletin ... the leading plasma-based pharmaceutical companies in the,People,s Republic ... will present at the upcoming China Rising Conference ... on May 18, 2009 and the 3rd Annual ...
... May 15 /PRNewswire-Asia/ -- Tiens Biotech Group (USA), Inc. (the,"Company" ... , today,announced financial results for the first quarter ended ... the first quarter of 2009 increased 42% to $18.2 million,compared ... a,significant increase in international sales. , ...
... MUNICH, May 15 , ... Addressing the,Challenges of Getting to Blood Pressure Goal ... The SHARE steering committee announce ... (SHARE) program on World,Hypertension Day 2009 (17th May). ...
Cached Biology Technology:China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 2China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 4Tiens Biotech Group (USA) Reports First Quarter Results 2Tiens Biotech Group (USA) Reports First Quarter Results 3Tiens Biotech Group (USA) Reports First Quarter Results 4Tiens Biotech Group (USA) Reports First Quarter Results 5Tiens Biotech Group (USA) Reports First Quarter Results 6Tiens Biotech Group (USA) Reports First Quarter Results 7Tiens Biotech Group (USA) Reports First Quarter Results 8Tiens Biotech Group (USA) Reports First Quarter Results 9Tiens Biotech Group (USA) Reports First Quarter Results 10Tiens Biotech Group (USA) Reports First Quarter Results 11SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 2SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 3SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 4SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal 5
(Date:8/21/2014)... Beth Israel Deaconess Medical Center (BIDMC ) are among ... Scientific Minds 2014," a comprehensive list compiled ... for science metrics and research performance analysis. ... "are performing and publishing work that their peers recognized ... to a Thomson Reuters statement. Researchers were identified based ...
(Date:8/21/2014)... A study recently published in the journal Carcinogenesis ... a new role for the protein adenomatous polyposis coli ... of cancer-related deaths in the U.S. , Lead author ... Biosciences and co-leader of the Cancer Biology program at ... of her career trying to understand the various activities ...
(Date:8/21/2014)... involves the pancreas digesting itself resulting in severe abdominal ... UK around 20,000 patients are diagnosed with the disease ... and treatment is restricted to intravenous fluid and nutritional ... of Life Sciences, who led the research, said "The ... gall stones and excessive alcohol intake combined with a ...
Breaking Biology News(10 mins):BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Insulin offers new hope for the treatment of acute pancreatitis 2
... Remote reefs can be tougher than they look,Western Australia,s ... Isolated coral reefs can recover from catastrophic damage ... long-term study by marine biologists from the Australian Institute ... Excellence for Coral Reef Studies (CoECRS) has shown. ...
... today announced it would fund its three Bioenergy ... to continued congressional appropriations. The three Centers including ... Ridge National Laboratory, the Great Lakes Bioenergy Research ... in partnership with Michigan State University, and the ...
... Nature Conservancy, and Central Michigan University have presented their findings ... study published in the Canadian Journal of Fisheries and ... we have found no evidence that Asian carp are widespread ... Lake Michigan and parts of lakes Erie and St Clair," ...
Cached Biology News:Remote reefs can be tougher than they look 2Remote reefs can be tougher than they look 3Energy Department announces 5-year renewal of funding for Bioenergy Research Centers 2Notre Dame study finds Asian carp DNA not widespread in the Great Lakes 2
... strain containing an overproducing clone of T4 DNA ... of a phosphodiester bond between juxtaposed 5' ... RNA. It repairs single-stranded nicks in duplex DNA, ... blunt-end and cohesive-end fragments of duplex DNA or ...
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
ANTI STENOTROPHOMONAS MALTOPHILIA...
Biology Products: